Creative Processes and Children With a Neurodeveloppement Disorder (CREADEV)

September 2, 2026 updated by: Assistance Publique - Hôpitaux de Paris

Study of Creative Processes in Children Aged 6 to 12 With a Neurodeveloppement Disorder

Neurodevelopmental disorders (NDDs) are associated with diverse cognitive profiles, including creative abilities that remain poorly documented. Studying creative processes in children helps to deepen our understanding of cognitive and developmental functioning in NDDs and to explore the development of more appropriate and inclusive assessment and support tools

Study Overview

Status

Not yet recruiting

Detailed Description

Once consent has been obtained, the assessments are carried out within the Child and Adolescent Psychiatry Department at Robert-Debré Hospital.

The verbal and figural tests will be administered by a neuropsychologist or a trained doctor, following a standardised procedure:

  • AUT (verbal)
  • Ocsai-D
  • LEGO building task
  • Paediatric ICAA parent questionnaire

Study Type

Observational

Enrollment (Estimated)

212

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Paris, France, 75019
        • Hôpital Robert Debré
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Children aged between 6 and 12 with a neurodevelopmental disorder, who are hospitalised in the ward.

Description

Inclusion Criteria:

  • Children aged 6 to 12 years
  • Prior inclusion in one of the existing clinical cohorts
  • No objection from those with parental authority
  • Consent from the participant, who must have read and understood the information leaflet
  • No acute malnutrition or acute medical condition

Exclusion Criteria:

  • Acute malnutrition or ongoing parenteral nutrition
  • Acute intercurrent medical condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Composite creative Score
Time Frame: 5 years
To characterise performance in creativity and divergent thinking among patients with TND, using a range of stimuli
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
paediatric adaptation of the Inventory of Creative Activities and Achievement (ICAA).
Time Frame: A parent-completed questionnaire on children's creative achievements
At day 1
A parent-completed questionnaire on children's creative achievements

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mylène FEFEU, MD, Assistance Publique - Hôpitaux de Paris

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 15, 2026

Primary Completion (Estimated)

September 15, 2031

Study Completion (Estimated)

September 15, 2031

Study Registration Dates

First Submitted

August 28, 2026

First Submitted That Met QC Criteria

September 2, 2026

First Posted (Actual)

September 3, 2026

Study Record Updates

Last Update Posted (Actual)

September 3, 2026

Last Update Submitted That Met QC Criteria

September 2, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • APHP260156
  • 2026-A00346-45 (Other Identifier: ANSM- IDRCB)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe